About Telix Pharmaceuticals
Telix Pharmaceuticals develops and sells products for diagnosing and treating cancer and rare diseases using targeted radiation. Their products help healthcare providers make better treatment decisions and offer personalized therapy for patients with significant medical needs. The company focuses on areas like prostate and kidney cancers, glioma, sarcoma, and bone marrow conditioning. Telix has a strong global supply chain to ensure their products are available worldwide, generating revenue through sales to healthcare institutions. They prioritize sustainability, patient care, and ethical practices, aiming to create value for patients, shareholders, and employees.
Melbourne, AustraliaHeadquarters
2015Year Founded
$14.8MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees
Benefits
Annual Performance Bonus
Equity-Based Incentive Program
Paid Vacation
Paid Wellness Days
Hybrid Work Options
Remote Work Options
Risks
Increased competition from Novartis and Bayer in the radiopharmaceutical market.
Regulatory challenges could delay approval of new radiopharmaceuticals.
Potential supply chain disruptions due to global shortages of key isotopes.
Differentiation
Telix specializes in molecularly-targeted radiation therapy for cancer and rare diseases.
The company focuses on urologic, neuro-oncology, and musculoskeletal oncology therapeutic areas.
Telix integrates sustainability and ethical practices into its operations and patient care.
Upsides
Acquisition of ImaginAb enhances Telix's pipeline with next-generation therapeutic candidates.
Partnership with Curium Pharma expands Scintimun® commercialization and market reach.
New cyclotrons in Brussels South boost production capacity for radioisotopes.
Funding
Total raised$14.79 M
Latest valuation$128.00 M
StageIPO
POST IPO CONVERTIBLE
6/30/2024$388
GRANT
3/31/2022$15
POST IPO EQUITY
12/31/2021$110
IPO
10/31/2017$32
$128.00 M